Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sertraline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 5/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sertraline SCHEMBL29690831 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL29374222 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL14028076 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL3885286 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL7922153 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL3947169 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL30244837 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL3856872 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL137619 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL137618 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009019412-A1 | RACEMISATION PROCESS FOR OBTAINING (1S,4S) N-METHYL-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENEAMINE (SERTRALINE) | NPIL PHARMACEUTICALS (UK) LIMITED (GB) | 2009-02-12 | — | — | WO | claimed |
| US-7408082-B1 | Racemisation process | NPIL PHARMACEUTICALS (UK) LIMITED (GB) | 2008-08-05 | — | — | US | claimed |
| US-20060014838-A1 | Process for converting trans-sertraline to cis-sertraline | DR. REDDY'S LABORATORIES, INC. | 2006-01-19 | — | — | US | claimed |
| EP-0386997-B1 | Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation, and as immunosuppressants | PFIZER (US) | 1997-03-19 | — | — | EP | claimed |
| EP-0575507-B1 | PROCESS FOR RECYCLING AMINE ISOMER | PFIZER (US) | 1996-01-31 | — | — | EP | claimed |
| EP-0575507-A1 | PROCESS FOR RECYCLING AMINE ISOMER. | PFIZER (US) | 1993-12-29 | — | — | EP | claimed |
| WO-1992015552-A1 | PROCESS FOR RECYCLING AMINE ISOMER | PFIZER INC. (US) | 1992-09-17 | — | — | WO | claimed |
| US-5082970-A | Process for recycling amine isomer | PFIZER INC. (US) | 1992-01-21 | — | — | US | claimed |
| EP-0028901-B1 | ANTIDEPRESSANT DERIVATIVES OF TRANS-4-PHENYL-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. (US) | 1983-03-02 | — | — | EP | claimed |
| EP-0028901-A1 | Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine and pharmaceutical compositions thereof | PFIZER INC. (US) | 1981-05-20 | — | — | EP | claimed |
| US-11931366-B2 | Compositions and methods of use thereof for treatment of proteinopathies | WASHINGTON UNIVERSITY (US) | 2024-03-19 | — | — | US | disclosed |
| US-20210228591-A1 | COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF PROTEINOPATHIES | WASHINGTON UNIVERSITY | 2021-07-29 | — | — | US | disclosed |
| WO-2019204764-A1 | COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF PROTEINOPATHIES | WASHINGTON UNIVERSITY (US) | 2019-10-24 | — | — | WO | disclosed |
| US-10266481-B2 | Organocatalytic asymmetric synthesis of antidepressants | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2019-04-23 | — | — | US | disclosed |
| EP-2455075-B1 | Process for Preparation of trans 4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine | SUNOVION PHARMACEUTICALS INC (US) | 2018-06-20 | — | — | EP | disclosed |
| WO-1992015552-A1 | PROCESS FOR RECYCLING AMINE ISOMER | PFIZER INC. (US) | 1992-09-17 | — | — | WO | disclosed |
| US-5082970-A | Process for recycling amine isomer | PFIZER INC. (US) | 1992-01-21 | — | — | US | disclosed |
| US-4556676-A | Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine | PFIZER INC. (US) | 1985-12-03 | — | — | US | disclosed |
| EP-0028901-B1 | ANTIDEPRESSANT DERIVATIVES OF TRANS-4-PHENYL-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. (US) | 1983-03-02 | — | — | EP | disclosed |
| EP-0028901-A1 | Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine and pharmaceutical compositions thereof | PFIZER INC. (US) | 1981-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10266481-B2 | Organocatalytic asymmetric synthesis of antidepressants | TPH1, NAT1, TPH2 | SLC6A4 14/4885MEN1 1676/4885KMT2A 1181/4885 |
| US-11931366-B2 | Compositions and methods of use thereof for treatment of proteinopathies | SERPINA2, FABP1, TTR | SLC6A4 4188/4885MEN1 3457/4885KMT2A 4403/4885 |
| US-20210228591-A1 | COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF PROTEINOPATHIES | SERPINA2, FABP1, TTR | SLC6A4 4188/4885MEN1 3457/4885KMT2A 4403/4885 |
| US-20060014838-A1 | Process for converting trans-sertraline to cis-sertraline | SLC6A4, TPH1, HTR4 | SLC6A4 1/4885MEN1 1007/4885KMT2A 2072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.